UNSPSC 51132243: Choline salicylate/magnesium salicylate

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN103. This VA Drug Class (CN103) classifies this compound as belonging to the group NON-OPIOID ANALGESICS.

UNSPSC 51132243 Choline salicylate/magnesium salicylate is a Commodity code that captures pharmaceutical products and over-the-counter medications purchased by state and local health agencies, though recent solicitations under this code show state and local governments buying a broader range of pharmaceutical and health-related supplies than the code's nominal scope suggests. The actual procurement activity includes naloxone and drug deactivation systems, generic multi-source pharmaceuticals and OTC products through cooperative purchasing arrangements, and therapeutic pharmacy initiative programs. Issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, MMCAP). State agencies use cooperative purchasing vehicles to aggregate demand and negotiate pricing across multiple jurisdictions, reflecting a trend toward centralized procurement of pharmaceutical inventory.

Recent activity concentrates in Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026 (response deadline July 26, 2023) seeking 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries to its Community Health Building in Sanford, using fixed-fee pricing and requiring E-Verify compliance, workers' compensation, and commercial general liability insurance. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026 to gather vendor capabilities regarding direct-to-manufacturer prescription programs, seeking information about vendor experience with self-insured employers and state agencies and capacity for outcomes-based contracting models. The Minnesota Department of Administration issued RFP S1070000015802 through MMCAP on January 20, 2026 (response deadline March 26, 2026) to establish multiple contracts for generic pharmaceuticals and OTC products distributed across state and local facilities in Minnesota and Oregon, requiring cGMP and DSCSA compliance, relationships with authorized wholesalers AmerisourceBergen, Cardinal Health, and Morris & Dickson, and weighted evaluation favoring price competitiveness at 75 percent.